CORRECTION Open Access

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation



Muhammad Elnaggar^{1,2}, Sarita Agte¹, Paula Restrepo^{1,2}, Meghana Ram¹, David Melnekoff^{1,2,3}, Christos Adamopoulos^{1,2}, Mark M. Stevens⁴, Katerina Kappes¹, Violetta Leshchenko¹, Daniel Verina¹, Sundar Jagannath¹, Poulikos I. Poulikakos^{1,2}, Samir Parekh¹ and Alessandro Laganà^{1,2,5*}

Correction: Journal of Hematology & Oncology (2022) 15:109

https://doi.org/10.1186/s13045-022-01330-3

The authors of the original article [1] mistakenly omitted a Funding source which is stated ahead: Alessandro Lagana was supported by the ASH Bridge Grant Award.

Published online: 08 May 2023

Reference

 Elnaggar M, et al. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. J Hematol Oncol. 2022;15:109. https://doi.org/10.1186/ s13045-022-01330-3.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1186/s13045-022-01330-3.

*Correspondence:

Alessandro Laganà

alessandro.lagana@mssm.edu

- ¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ³ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ⁴Travera, Medford, MA, USA
- ⁵ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.